Ivabradine is a novel medication used for the symptomatic management of stable angina pectoris. Ivabradine acts by reducing the heart rate via specific inhibition of the funny channel, a mechanism different from that of beta blockers and calcium channel blockers, two commonly prescribed antianginal drugs. Ivabradine is a cardiotonic agent. Ivabradine was approved in 2015. Ivabradine acts on the If (f is for "funny", so called because it had unusual properties compared with other current systems known at the time of its discovery) ion current, which is highly expressed in the sinoatrial node. If is a mixed Na+–K+ inward current activated by hyperpolarization and modulated by the autonomic nervous system. It is one of the most important ionic currents for regulating pacemaker activity in the sinoatrial (SA) node. Ivabradine selectively inhibits the pacemaker If current in a dose-dependent manner. Blocking this channel reduces cardiac pacemaker activity, slowing the heart rate and allowing more time for blood to flow to the myocardium.
Pang, Yalong; Liu, Peihua. Process for preparation of Ivabradine and pharmaceutically acceptable salts. CN 101544605. (Assignee Beijing Shenlanhai Bio-Pharmaceutical Science and Technology Co., Ltd., Peop. Rep. China)
Lerestif, Jean-Michel; Lecouve, Jean-Pierre; Souvie, Jean-Claude; Brigot, Daniel; Horvath, Stephane; Auguste, Marie-Noelle; Damien, Gerard. Process for the preparation of ivabradine via hydrogenation of oxobenzazepinepropanal acetal derivative and coupling with dimethoxycyclobutabenzenemethanamine. US 20050228177. (nee Les Laboratoires Servier, Fr.)
Dwivedi, Shriprakash Dhar; Kumar, Rajiv; Patel, Sunil Tribhovandas; Shah, Alpeshkumar Parvin Chandra. Process for preparation of ivabradine hydrochloride. WO 2008065681. (Assignee Cadila Healthcare Limited, India)
Luo, Junzhi; Yan, Yimin; Tu, Yongrui. Process for preparation of Ivabradine hydrochloride and its stable crystal form. WO 2008125006. (Assignee UTOpharm (Shanghai) Co., Ltd., Peop. Rep. China; Changzhou No.4 Pharmaceutical Factory Co., Ltd.)
Bose, Prosenjit; Siripalli, Udaya Bhaskara Rao; Kandadai, Appan Srinivas. Process for preparation of ivabradine via resolution of N-[[3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]-N-methylamine. WO 2010072409. (Assignee Krka, d.d., Slovenia)
Bose, Prosenjit; Siripalli, Udaya Bhaskara Rao; Kandadai, Appan Srinivas. Process for preparation of ivabradine via resolution of N-[[3,4-dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]-N-methylamine. WO 2010072409. (Assignee Krka, d.d., Slovenia)
Peglion, Jean-Louis; Caignard, Pascal; Lerestif, Jean-Michel; Lecouve, Jean-Pierre. New methods for the synthesis of ivabradine and its pharmaceutically acceptable acid addition salts via alkylation and catalytic hydrogenation. WO 2011033194. (Assignee Les Laboratoires Servier, Fr.)
Ujvari, Viktor; Bodi, Jozsef; Farago, Janos; Szoke, Katalin; Faigl, Ferenc; Nemet, Zoltan; Temesvari, Krisztina; Kiss, Robert; Matravolgyi, Bela; Kassai, Ferencne; Kiss-Bartos, Dorottya. Method for preparation of ivabradine salts. WO 2011138625. (Assignee Richter Gedeon Nyrt., Hung.)
Ioannou, Savvas; Sergides, Christakis; Pitta, Daphne; Pittas, Andreas. preparation of new salt of ivabradine and uses thereof. WO 2018115181. (Assignee Biogena (A.P.I) Ltd, Cyprus)
Sun, Haiyu; Chen, Dong; Wei, Congcong; Wang, Jianyao; Wang, Xiaobo. Preparation method of high-purity ivabradine hydrochloride. CN 108424390. (Assignee Yangtze River Pharmaceutical Group Beijing Haiyan Pharmaceutical Co., Ltd., Peop. Rep. China; Yangtze River Pharmaceutical Group Co., Ltd.)
